Brentuximab vedotin

Stephen M. Ansell

doi:10.1182/blood-2014-06-537514

Brentuximab vedotin

Stephen M. Ansell

Hematology

Research output: Contribution to journal › Review article › peer-review

63 Scopus citations

Abstract

Brentuximab vedotin is an anti-CD30 antibody-drug conjugate with proven efficacy in patients with CD30⁺ malignancies, including classical Hodgkin lymphoma and anaplastic large cell lymphoma. Promising activity has also been seen in other lymphomas that express CD30. Because of its acceptable toxicity profile and significant clinical efficacy, single-agent brentuximab vedotin is an approved treatment for relapsed patients with these diseases. Brentuximab vedotin has safely been combined with chemotherapy and is now being compared with standard treatments in randomized trials.

Original language	English (US)
Pages (from-to)	3197-3200
Number of pages	4
Journal	Blood
Volume	124
Issue number	22
DOIs	https://doi.org/10.1182/blood-2014-06-537514
State	Published - Nov 20 2014

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood-2014-06-537514

Cite this

@article{0faad27537df404cb322bff698b57271,

title = "Brentuximab vedotin",

abstract = "Brentuximab vedotin is an anti-CD30 antibody-drug conjugate with proven efficacy in patients with CD30+ malignancies, including classical Hodgkin lymphoma and anaplastic large cell lymphoma. Promising activity has also been seen in other lymphomas that express CD30. Because of its acceptable toxicity profile and significant clinical efficacy, single-agent brentuximab vedotin is an approved treatment for relapsed patients with these diseases. Brentuximab vedotin has safely been combined with chemotherapy and is now being compared with standard treatments in randomized trials.",

author = "Ansell, {Stephen M.}",

note = "Publisher Copyright: {\textcopyright} 2014 by The American Society of Hematology.",

year = "2014",

month = nov,

day = "20",

doi = "10.1182/blood-2014-06-537514",

language = "English (US)",

volume = "124",

pages = "3197--3200",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "22",

}

TY - JOUR

T1 - Brentuximab vedotin

AU - Ansell, Stephen M.

PY - 2014/11/20

Y1 - 2014/11/20

N2 - Brentuximab vedotin is an anti-CD30 antibody-drug conjugate with proven efficacy in patients with CD30+ malignancies, including classical Hodgkin lymphoma and anaplastic large cell lymphoma. Promising activity has also been seen in other lymphomas that express CD30. Because of its acceptable toxicity profile and significant clinical efficacy, single-agent brentuximab vedotin is an approved treatment for relapsed patients with these diseases. Brentuximab vedotin has safely been combined with chemotherapy and is now being compared with standard treatments in randomized trials.

AB - Brentuximab vedotin is an anti-CD30 antibody-drug conjugate with proven efficacy in patients with CD30+ malignancies, including classical Hodgkin lymphoma and anaplastic large cell lymphoma. Promising activity has also been seen in other lymphomas that express CD30. Because of its acceptable toxicity profile and significant clinical efficacy, single-agent brentuximab vedotin is an approved treatment for relapsed patients with these diseases. Brentuximab vedotin has safely been combined with chemotherapy and is now being compared with standard treatments in randomized trials.

UR - http://www.scopus.com/inward/record.url?scp=84911385117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911385117&partnerID=8YFLogxK

U2 - 10.1182/blood-2014-06-537514

DO - 10.1182/blood-2014-06-537514

M3 - Review article

C2 - 25293772

AN - SCOPUS:84911385117

SN - 0006-4971

VL - 124

SP - 3197

EP - 3200

JO - Blood

JF - Blood

IS - 22

ER -

Brentuximab vedotin

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this